M Markman

581 total citations
15 papers, 436 citations indexed

About

M Markman is a scholar working on Surgery, Pathology and Forensic Medicine and Reproductive Medicine. According to data from OpenAlex, M Markman has authored 15 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 7 papers in Pathology and Forensic Medicine and 7 papers in Reproductive Medicine. Recurrent topics in M Markman's work include Ovarian cancer diagnosis and treatment (7 papers), Intraperitoneal and Appendiceal Malignancies (6 papers) and Chemotherapy-induced organ toxicity mitigation (5 papers). M Markman is often cited by papers focused on Ovarian cancer diagnosis and treatment (7 papers), Intraperitoneal and Appendiceal Malignancies (6 papers) and Chemotherapy-induced organ toxicity mitigation (5 papers). M Markman collaborates with scholars based in United States and Brazil. M Markman's co-authors include Stephen C. Rubin, Thomas B. Hakes, Lois Almadrones, William J. Hoskins, John L. Lewis, Bonnie Reichman, W.J. Hoskins, Walter B. Jones, J. L. Lewis and Wanda K. Jones and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Obstetrics and Gynecology and Gynecologic Oncology.

In The Last Decade

M Markman

14 papers receiving 417 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M Markman United States	9	329	214	145	108	78	15	436
H D Homesley United States	9	468 1.4×	335 1.6×	163 1.1×	218 2.0×	65 0.8×	12	611
C. Madroñal Spain	4	446 1.4×	176 0.8×	153 1.1×	254 2.4×	61 0.8×	11	533
M.G. Salerno Italy	12	233 0.7×	147 0.7×	93 0.6×	135 1.3×	21 0.3×	13	334
J Tigaud France	10	199 0.6×	122 0.6×	162 1.1×	154 1.4×	26 0.3×	22	378
Decker Dg United States	12	375 1.1×	154 0.7×	136 0.9×	191 1.8×	74 0.9×	22	598
Melissa M. Thrall United States	11	451 1.4×	228 1.1×	144 1.0×	221 2.0×	24 0.3×	13	599
C. Coens Netherlands	3	624 1.9×	271 1.3×	155 1.1×	344 3.2×	75 1.0×	6	673
K. Wollschlaeger Germany	7	461 1.4×	296 1.4×	153 1.1×	182 1.7×	69 0.9×	11	555
Pan Liu China	4	349 1.1×	176 0.8×	150 1.0×	112 1.0×	45 0.6×	6	405
Alan C. Schlaerth United States	7	465 1.4×	136 0.6×	112 0.8×	407 3.8×	44 0.6×	7	659

Countries citing papers authored by M Markman

Since Specialization

Citations

This map shows the geographic impact of M Markman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Markman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Markman more than expected).

Fields of papers citing papers by M Markman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Markman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Markman. The network helps show where M Markman may publish in the future.

Co-authorship network of co-authors of M Markman

This figure shows the co-authorship network connecting the top 25 collaborators of M Markman. A scholar is included among the top collaborators of M Markman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Markman. M Markman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Markman, M. (2002). Assessing cancer clinical trials: will your patient benefit from a 'breakthrough'?. Cleveland Clinic Journal of Medicine. 69(5). 368–369. 1 indexed citations

Markman, M. (2001). Prolonged Symptom-Free Survival in a Patient with Persistent Primary Peritoneal Carcinoma and a Rising CA-125: A Note of Caution. Gynecologic Oncology. 81(3). 509–511. 2 indexed citations

Markman, M, Thomas Hakes, R. Barakat, et al.. (1996). Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer.. Journal of Clinical Oncology. 14(3). 796–799. 38 indexed citations

Markman, M. (1996). Intraperitoneal taxol. Cancer treatment and research. 81. 1–5. 9 indexed citations

Markman, M, Anuradha Koka, & Roger M. Macklis. (1995). Trends in radiation oncology: a review for the nononcologist. Cleveland Clinic Journal of Medicine. 62(4). 254–258. 1 indexed citations

Markman, M. (1994). Second‐line chemotherapy for refractory cancer: Intraperitoneal chemotherapy. Seminars in Surgical Oncology. 10(4). 299–304. 4 indexed citations

Markman, M, Thomas B. Hakes, Bonnie Reichman, et al.. (1992). Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.. Journal of Clinical Oncology. 10(2). 243–248. 108 indexed citations

Hakes, Thomas B., W.J. Hoskins, Walter B. Jones, et al.. (1992). Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecologic Oncology. 45(3). 284–289. 120 indexed citations

Casper, Ephraim S., et al.. (1991). A phase II trial of PALA+dipyridamole in patients with advanced soft-tissue sarcoma. Cancer Chemotherapy and Pharmacology. 28(1). 51–54. 10 indexed citations

10.

Markman, M, Robert Rothman, Thomas B. Hakes, et al.. (1991). Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. Journal of Cancer Research and Clinical Oncology. 117(2). 89–90. 22 indexed citations

11.

Markman, M, Thomas B. Hakes, Bonnie Reichman, et al.. (1991). Single agent ifosfamide (IFOS) therapy of ovarian cancer (OC) previously treated with cisplatin (CIS). Gynecologic Oncology. 40(2). 190–190. 2 indexed citations

12.

Rubin, Stephen C., William J. Hoskins, Thomas B. Hakes, et al.. (1989). Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. American Journal of Obstetrics and Gynecology. 160(3). 667–671. 76 indexed citations

13.

Markman, M, Stephen Cleary, William E. Lucas, Regis J. Weiss, & Howell Sb. (1986). Ip chemotherapy employing a regimen of cisplatin, cytarabine, and bleomycin.. PubMed. 70(6). 755–60. 14 indexed citations

14.

Markman, M, et al.. (1985). Intraperitoneal chemotherapy for ovarian carcinoma. Cancer treatment and research. 41(8). 179–212. 6 indexed citations

15.

Markman, M, et al.. (1985). Intensive alternating chemotherapy regimen in small cell carcinoma of the lung.. PubMed. 69(2). 161–6. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact